Celldex Therapeutics, Inc.

Celldex Therapeutics is a biopharmaceutical company developing therapeutic antibodies targeting severe inflammatory, allergic, and autoimmune conditions. The company focuses on monoclonal and bispecific antibody candidates designed to address mast cell-mediated diseases where existing treatments offer limited efficacy. Its lead clinical program, Barzolvolimab (CDX-0159), is a monoclonal antibody that binds the KIT receptor to inhibit mast cell activation. The company is evaluating this candidate across multiple indications including chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. A second clinical-stage program, CDX-622, is a bispecific antibody designed to address chronic inflammation through dual mechanisms: neutralizing thymic stromal lymphopoietin and depleting mast cells via stem cell factor inhibition.

The company operates with a focused research and development structure supporting its clinical pipeline. Celldex maintains its headquarters in Hampton, New Jersey, and operates with approximately 186 full-time employees. As a pre-commercial biopharmaceutical organization, the company's operations are concentrated on advancing its clinical candidates rather than generating product revenues. The company is incorporated in Delaware and trades on the Nasdaq exchange.